Home > Publications Database > Therapeutic Potential of Amyloid-β Interactors in Rapidly Progressive Alzheimer's Disease-An In Silico Study. > print

001     285249
005     20260304110136.0
024 7 _ |a 10.1002/minf.70024
|2 doi
024 7 _ |a pmid:41692408
|2 pmid
024 7 _ |a 1868-1743
|2 ISSN
024 7 _ |a 0722-3676
|2 ISSN
024 7 _ |a 0931-8771
|2 ISSN
024 7 _ |a 1521-3838
|2 ISSN
024 7 _ |a 1611-020X
|2 ISSN
024 7 _ |a 1611-0218
|2 ISSN
024 7 _ |a 1868-1751
|2 ISSN
037 _ _ |a DZNE-2026-00191
041 _ _ |a English
082 _ _ |a 530
100 1 _ |a Saeed, Sania
|b 0
245 _ _ |a Therapeutic Potential of Amyloid-β Interactors in Rapidly Progressive Alzheimer's Disease-An In Silico Study.
260 _ _ |a Weinheim
|c 2026
|b Wiley-VCH-Verl.
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1772542388_20775
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Rapidly progressive Alzheimer's disease (rpAD) is a rare but severe form of Alzheimer's disease characterized by accelerated cognitive decline and limited therapeutic options. Conventional anti-amyloid-β interventions have shown little success due to poor target specificity, neurotoxicity, and lack of efficacy, underscoring the need for novel therapeutic strategies. This study aimed to identify and prioritize molecular targets associated with rpAD by investigating the protein interactome of amyloid-β (Aβ42) using integrative computational approaches. Functional enrichment, protein-protein interaction network analysis, and community clustering revealed that rpAD-specific Aβ42 interactors were predominantly involved in mitochondrial bioenergetics, redox regulation, and cytoskeletal stability, pathways central to neuronal survival and synaptic function. Molecular docking identified fumarate hydratase, carbonyl reductase 1, and the F-actin capping protein as high-affinity interactors of Aβ42, linking these proteins to energy failure, oxidative stress, and synaptic dysfunction. Virtual screening of a therapeutic drug library against fumarate hydratase identified several compounds with strong binding affinities, among which quinestrol, estradiol benzoate, norethindrone, tamibarotene, drospirenone, and ketanserin emerged as lead candidates. Pharmacokinetic profiling, including ADMET modeling, confirmed their blood-brain barrier permeability and drug-likeness, supporting their potential as central nervous system active agents. Together, this work highlights key molecular targets in rpAD and proposes repurposed, pharmacologically diverse compounds with multitarget neuroprotective potential. By utilizing in silico analysis, the study provides a rational framework for target discovery and drug prioritization in rpAD, offering a foundation for future experimental validation and the development of translational research.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Aβ interactors
|2 Other
650 _ 7 |a molecular docking
|2 Other
650 _ 7 |a pharmacokinetics
|2 Other
650 _ 7 |a rapidly progressive Alzheimer's disease
|2 Other
650 _ 7 |a rpAD
|2 Other
650 _ 7 |a virtual screening
|2 Other
650 _ 7 |a Amyloid beta-Peptides
|2 NLM Chemicals
650 _ 2 |a Alzheimer Disease: drug therapy
|2 MeSH
650 _ 2 |a Alzheimer Disease: metabolism
|2 MeSH
650 _ 2 |a Amyloid beta-Peptides: metabolism
|2 MeSH
650 _ 2 |a Amyloid beta-Peptides: chemistry
|2 MeSH
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Molecular Docking Simulation
|2 MeSH
650 _ 2 |a Computer Simulation
|2 MeSH
650 _ 2 |a Protein Interaction Maps
|2 MeSH
700 1 _ |a Khan, Shahrukh
|b 1
700 1 _ |a Noor, Aneeqa
|0 P:(DE-2719)9001208
|b 2
700 1 _ |a Zerr, Inga
|0 P:(DE-2719)2000058
|b 3
|u dzne
700 1 _ |a Zafar, Saima
|0 P:(DE-2719)9000358
|b 4
|e Last author
|u dzne
773 _ _ |a 10.1002/minf.70024
|g Vol. 45, no. 2, p. e70024
|0 PERI:(DE-600)2537668-8
|n 2
|p e70024
|t Molecular informatics
|v 45
|y 2026
|x 1868-1743
856 4 _ |u https://pub.dzne.de/record/285249/files/DZNE-2026-00191%20SUP.zip
856 4 _ |u https://pub.dzne.de/record/285249/files/DZNE-2026-00191.pdf
|y Restricted
856 4 _ |u https://pub.dzne.de/record/285249/files/DZNE-2026-00191.pdf?subformat=pdfa
|x pdfa
|y Restricted
909 C O |o oai:pub.dzne.de:285249
|p VDB
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 3
|6 P:(DE-2719)2000058
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 4
|6 P:(DE-2719)9000358
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
914 1 _ |y 2026
915 _ _ |a DEAL Wiley
|0 StatID:(DE-HGF)3001
|2 StatID
|d 2025-11-12
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2025-11-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2025-11-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2025-11-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2025-11-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2025-11-12
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2025-11-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2025-11-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2025-11-12
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2025-11-12
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b MOL INFORM : 2022
|d 2025-11-12
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2025-11-12
920 1 _ |0 I:(DE-2719)1440011-1
|k AG Zerr
|l Translational Studies and Biomarker
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-2719)1440011-1
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21